{"id":592434,"date":"2022-03-22T21:09:01","date_gmt":"2022-03-22T21:09:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=592434"},"modified":"2022-03-22T21:09:01","modified_gmt":"2022-03-22T21:09:01","slug":"idiopathic-pulmonary-fibrosis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market_592434.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1647856779.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Idiopathic Pulmonary Fibrosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1647856779.jpeg\" alt=\"Idiopathic Pulmonary Fibrosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Idiopathic Pulmonary Fibrosis Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> &#8220;Idiopathic Pulmonary Fibrosis &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s &ldquo;Idiopathic Pulmonary Fibrosis &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime; report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> Idiopathic Pulmonary Fibrosis Market Report:<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent population of Idiopathic Pulmonary Fibrosis (IPF)&nbsp; in the 7MM is expected to rise during the study period [2017&ndash;2030]. Estimates show the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF)&nbsp; is in the United States followed by the UK.&nbsp;<\/li>\n<li>According to DelveInsight&rsquo;s analysis, it has been observed that Moderate Idiopathic Pulmonary Fibrosis (IPF)&nbsp; cases are more prominent in comparison to Mild and Severe cases across 7 MM.<\/li>\n<li>Among the European 5 countries, the United Kingdom had the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF), followed by Italy and Germany. On the other hand, Spain had the lowest prevalent population of IPF. The highest rates of IPF in Europe are reported in the UK, with incidence rates between 4.6 and 8.65 per 100\u200a000 people per year, and almost 6000 people diagnosed annually&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Idiopathic Pulmonary Fibrosis market report covers a descriptive overview and comprehensive insight of the Idiopathic Pulmonary Fibrosis Epidemiology and Idiopathic Pulmonary Fibrosis&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Idiopathic Pulmonary Fibrosis market report provides insights on the current and emerging therapies.<\/li>\n<li>Idiopathic Pulmonary Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Idiopathic Pulmonary Fibrosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Idiopathic Pulmonary Fibrosis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Idiopathic Pulmonary Fibrosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes including genetic susceptibility, environmental risk factors, and exposures have been suggested in the literature. All of these cause repetitive micro-injury to the lung tissue and vasculature, which triggers a cascade of inflammatory response and fibrosis.<\/p>\n<p style=\"text-align: justify;\"><strong>Idiopathic Pulmonary Fibrosis Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The dynamics of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis market<\/a> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, and others during the forecasted period 2018-2030.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Idiopathic Pulmonary Fibrosis Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pamrevlumab: FibroGen<\/li>\n<li>KD025: Kadmon Corporation<\/li>\n<li>PRM-151: Promedior<\/li>\n<li>GLPG1690: Galapagos<\/li>\n<li>Tipelukast: MediciNova<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Idiopathic Pulmonary Fibrosis Market Drivers&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The grant of special regulatory designations&nbsp;<\/li>\n<li>Several therapies in the pipeline from various companies&nbsp;<\/li>\n<li>An increase in the prevalence of fibrotic diseases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Idiopathic Pulmonary Fibrosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Idiopathic Pulmonary Fibrosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Idiopathic Pulmonary Fibrosis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Idiopathic Pulmonary Fibrosis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Idiopathic Pulmonary Fibrosis Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Pulmonary Fibrosis market. A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Idiopathic Pulmonary Fibrosis&nbsp; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Pulmonary Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=idiopathic-pulmonary-fibrosis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Idiopathic Pulmonary Fibrosis Market DelveInsight&#8217;s &#8220;Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market_592434.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-592434","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=592434"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/592434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=592434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=592434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=592434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}